John B. Kisiel, Brian A. Dukek, Reddappa V.S.R. Kanipakam, Hassan M. Ghoz, Tracy C. Yab, Calise K. Berger, William R. Taylor, Patrick H. Foote, Nasra H. Giama, Kristeen Onyirioha, Mohamed A. Abdallah, Kelli N. Burger, Seth W. Slettedahl, Douglas W. Mahoney, Thomas C. Smyrk, Jason T. Lewis, Maria Giakoumopoulos, Hatim T. Allawi, Graham P. Lidgard, Lewis R. Roberts, David A. Ahlquist – 31 August 2018 – Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed.

Yongjun Tian, Jing‐hsiung James Ou – 31 August 2018

Marlyn J. Mayo, Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, Andrew J. Muir, Lei Ling, Stephen J. Rossi, Alex M. DePaoli – 30 August 2018 – Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth factor (FGF) 19 is a hormone that acts directly in the liver to regulate bile acid synthesis.

Omar Motiño, Daniel E. Francés, Natalia Casanova, Marina Fuertes‐Agudo, Carme Cucarella, Juana M. Flores, María Teresa Vallejo‐Cremades, Luis Olmedilla, José Pérez Peña, Rafael Bañares, Lisardo Boscá, Marta Casado, Paloma Martín‐Sanz – 29 August 2018 – Liver ischemia and reperfusion injury (IRI) remains a serious clinical problem affecting liver transplantation outcomes. IRI causes up to 10% of early organ failure and predisposes to chronic rejection. Cyclooxygenase‐2 (COX‐2) is involved in different liver diseases, but the significance of COX‐2 in IRI is a matter of controversy.

Yongsheng Li, Daniel J. McGrail, Juan Xu, Junyi Li, Ning‐Ning Liu, Ming Sun, Richard Lin, Rita Pancsa, Jiwei Zhang, Ju‐Seog Lee, Hui Wang, Gordon B. Mills, Xia Li, Song Yi, Nidhi Sahni – 28 August 2018 – The interaction between RNA‐binding proteins (RBPs) and RNA plays an important role in regulating cellular function. However, decoding genome‐wide protein–RNA regulatory networks as well as how cancer‐related mutations impair RNA regulatory activities in hepatocellular carcinoma (HCC) remains mostly undetermined.

Ann Robinson, Hesam Tavakoli, Benny Liu, Taft Bhuket, Robert J. Wong – 28 August 2018 – Individuals from the 1945‐1965 birth cohort account for the majority of hepatocellular carcinoma (HCC) cases in the United States. Understanding trends in HCC among this birth cohort is vital given the increasing burden of chronic liver disease among this group. We retrospectively evaluated trends and disparities in HCC tumor stage at the time of diagnosis among the 1945‐1965 birth cohort in the United States using the Surveillance, Epidemiology, and End Results (SEER) cancer registry.

Andrew J. Muir, Cynthia Levy, Harry L.A. Janssen, Aldo J. Montano‐Loza, Mitchell L. Shiffman, Stephen Caldwell, Velimir Luketic, Dora Ding, Catherine Jia, Bryan J. McColgan, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Michael Manns, Roger Chapman, Nezam H. Afdhal, Zachary Goodman, Bertus Eksteen, Christopher L. Bowlus, for the GS‐US‐321‐0102 Investigators – 28 August 2018 – Lysyl oxidase like‐2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC).

Jonggi Choi, Gi‐Ae Kim, Seungbong Han, Woochang Lee, Sail Chun, Young‐Suk Lim – 28 August 2018 – We aimed to determine the surveillance performance of alpha‐fetoprotein (AFP), lectin‐reactive AFP (AFP‐L3), des‐gamma‐carboxy prothrombin (DCP), and their combinations for the early detection of hepatocellular carcinoma (HCC) by using prospectively collected longitudinal samples in patients at risk.

A. Jasmine Bullard, Francesca E. Cunningham, Bryan D. Volpp, Elliott Lowy, Lauren A. Beste, Bernadette B. Heron, Mark Geraci, Julia M. Hammond, Kourtney LaPlant, Elise A. Stave, Marsha J. Turner, Meghan C. O’Leary, Michael J. Kelley, Christine M. Hunt – 28 August 2018 – Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti‐cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti‐CD20 Ab therapy averts hepatitis, chemotherapy disruption, and death.

Stefania Mantovani, Barbara Oliviero, Andrea Lombardi, Stefania Varchetta, Dalila Mele, Angelo Sangiovanni, Giorgio Rossi, Matteo Donadon, Guido Torzilli, Cristiana Soldani, Camillo Porta, Paolo Pedrazzoli, Silvia Chiellino, Roberto Santambrogio, Enrico Opocher, Marcello Maestri, Stefano Bernuzzi, Armando Rossello, Sophie Clément, Claudio De Vito, Laura Rubbia‐Brandt, Francesco Negro, Mario U. Mondelli – 28 August 2018 – The activating natural cytotoxicity receptor NKp30 is critical for natural killer (NK) cell function and tumor immune surveillance.